I have this nagging feeling that nothing is going to happen here until all patients from the U.S. group that were added after the FDA approved the trial can be included. Why enroll patients that won't count. I beleive Resverlogix knows quite well when that will be and explains why Don mentioned at the AGM they were going to continue dosing until they have a confirmed 250 events. This means it will take longer to process the data and determine the outcome for the primary end point. I am very suspicious why they do not announce the actual number of events at any point in time, they may be blinded but they must be given that number. Could it be the number was lower then the 200 that was eluded to at the AGM. I just don't get how they could be so far off their original date for initial primary end point data. This is just my opinon and why I beleive they are saying H1.